Pancreatic Cancer Research

ResearcherUniversity of ArizonaActive in the last 2 years

Aaron James Scott

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0301-3072; OpenAlex author ID A5025510544. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 2, last author 0)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 trial · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 trial

Papers 6

  1. A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer. Co-author DOI 10.1038/s43018-025-01029-7↗
  2. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Co-author DOI 10.1093/oncolo/oyaf271↗
  3. Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institu… Co-author DOI 10.21037/apc.2020.02.01↗
  4. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12123816↗
  5. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… First author DOI 10.1093/annonc/mdv264↗
  6. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… First author DOI 10.1093/annonc/mdv477↗

Trials 2

  1. GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer Principal investigator NCT07627191↗
  2. Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer Principal investigator NCT04820179↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Deirdre Jill Cohen · 3 shared papers, 2015–2025 · strength 0.29
  2. Wells A. Messersmith · 3 shared papers, 2015–2025 · strength 0.29
  3. Lawrence Leichman · 2 shared papers, 2015–2025 · strength 0.26
  4. Elliot Newman · 1 shared paper, 2025 · strength 0.22
  5. Tanios Bekaii‐Saab · 1 shared paper, 2025 · strength 0.22
  6. Colin D. Weekes · 1 shared paper, 2025 · strength 0.22
  7. Alec J. Megibow · 1 shared paper, 2025 · strength 0.22
  8. Paul E. Oberstein · 1 shared paper, 2025 · strength 0.22
  9. Zhiren Wang · 1 shared paper, 2025 · strength 0.22
  10. Jianqin Lu · 1 shared paper, 2025 · strength 0.22
  11. Alejandro Recio‐Boiles · 1 shared paper, 2020 · strength 0.11
  12. Ali McBride · 1 shared paper, 2020 · strength 0.11
  13. Hani M. Babiker · 1 shared paper, 2020 · strength 0.11
  14. Rachna T. Shroff · 1 shared paper, 2020 · strength 0.09
  15. Nina G. Steele · 1 shared paper, 2020 · strength 0.09
  16. Jayati L. Chakrabarti · 1 shared paper, 2020 · strength 0.09
  17. Pritha Adhikary · 1 shared paper, 2020 · strength 0.09
  18. Mohammad R. Khreiss · 1 shared paper, 2020 · strength 0.09
  19. Yana L. Zavros · 1 shared paper, 2020 · strength 0.09
  20. Loryn L. Holokai · 1 shared paper, 2020 · strength 0.09
  21. Juanita L. Merchant · 1 shared paper, 2020 · strength 0.09
  22. Joanne Lundy · 1 shared paper, 2020 · strength 0.09
  23. Syed Arif Ahmad · 1 shared paper, 2020 · strength 0.09
  24. Daniel Gerald Croagh · 1 shared paper, 2020 · strength 0.09
  25. Timothy L. Frankel · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.